800-845-6913
Tuteur Law Networks | Knowledge is Power.
May 14, 2008
Bayer will begin pulling remaining stock of Trasylol
Bayer AG will begin removing the remaining stock of the drug Trasylol, used to control bleeding, from warehouses and hospitals, the U.S. Food and Drug Administration said in a statement today.
Bayer, Germany’s largest drugmaker, halted Trasylol sales last year after a study linked the product to a 50 percent higher risk of death than competing drugs in patients undergoing heart surgery.
Trasylol was approved in the U.S. in 1993 to reduce transfusions and bleeding during open-heart surgery. It became a mainstay of care, generating about $333 million in 2005.
Access to Trasylol is limited to certain patients who are at an increased risk of blood loss and transfusions during heart bypass surgery and have no alternative treatments available, the FDA’s statement said.
Continue reading, Bayer will begin pulling remaining stock of Trasylol